» Articles » PMID: 12839868

Despite Increased Plasma Concentration, Inflammation Reduces Potency of Calcium Channel Antagonists Due to Lower Binding to the Rat Heart

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2003 Jul 4
PMID 12839868
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

1. Rheumatoid arthritis reduces verapamil oral clearance thereby increases plasma concentration of the drug. This coincides with reduced drug effects through an unknown mechanism. 2. The effect of interferon-induced acute inflammation on the pharmacokinetics and electrocardiogram of verapamil (20 mg kg(-1), p.o.) and nifedipine (0.1 mg kg(-1), i.v.) was studied in Sprague-Dawley rats. 3. The effect of both acute and chronic inflammation on radioligand binding to cardiac L-type calcium channels was also investigated. 4. Acute inflammation resulted in increased plasma concentration of verapamil but had no effect on that of nifedipine. Verapamil binding to plasma proteins was unaffected. 5. As has been reported for humans, the increased verapamil concentration coincided with a reduction in the degree to which PR interval is prolonged by the drug. The effect of nifedipine on PR interval was also reduced by inflammation. 6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation. 7. Incubation of the normal cardiac cell membranes with 100 and 1000 pg ml(-1) of rat tissue necrosis factor-alpha did not influence the binding indices to the calcium channels. 8. Our data suggest that the reduced calcium channel responsiveness is because of altered binding to channels.

Citing Articles

The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine.

Burhanuddin K, Mohammed A, Badhan R Pharmaceutics. 2024; 16(4).

PMID: 38675150 PMC: 11053426. DOI: 10.3390/pharmaceutics16040489.


Nimodipine systemic exposure and outcomes following aneurysmal subarachnoid hemorrhage: a pilot prospective observational study (ASH-1 study).

Mahmoud S, Hefny F, Isse F, Farooq S, Ling S, OKelly C Front Neurol. 2024; 14:1233267.

PMID: 38249736 PMC: 10796587. DOI: 10.3389/fneur.2023.1233267.


Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition.

Abdallah Y, Chahal S, Jamali F, Mahmoud S J Pharm Pharm Sci. 2023; 26:11137.

PMID: 36942294 PMC: 9990632. DOI: 10.3389/jpps.2023.11137.


Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative.

Alrushaid S, Sayre C, Yanez J, Forrest M, Senadheera S, Burczynski F Pharmaceutics. 2017; 9(3).

PMID: 28902176 PMC: 5620576. DOI: 10.3390/pharmaceutics9030035.


Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis.

Asghar W, Aghazadeh-Habashi A, Jamali F Inflammopharmacology. 2017; .

PMID: 28389995 DOI: 10.1007/s10787-017-0344-1.


References
1.
Prior P, Symmons D, Scott D, Brown R, HAWKINS C . Cause of death in rheumatoid arthritis. Br J Rheumatol. 1984; 23(2):92-9. DOI: 10.1093/rheumatology/23.2.92. View

2.
Piafsky K, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F . Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978; 299(26):1435-9. DOI: 10.1056/NEJM197812282992604. View

3.
Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, Hori R . Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. J Pharmacol Exp Ther. 1985; 235(2):513-20. View

4.
Descotes J . Immunomodulating agents and hepatic drug-metabolizing enzymes. Drug Metab Rev. 1985; 16(1-2):175-84. DOI: 10.3109/03602538508991434. View

5.
Peterson T, Renton K . Kupffer cell factor mediated depression of hepatic parenchymal cell cytochrome P-450. Biochem Pharmacol. 1986; 35(9):1491-7. DOI: 10.1016/0006-2952(86)90114-0. View